HLA II类免疫原性突变负荷预测免疫检查点阻断治疗应答
研究分析110例黑色素瘤和123例非小细胞肺癌(NSCLC)免疫检查点阻断(ICB)治疗患者的全外显子组数据,用MHCnuggets模型评估HLA II类免疫原性突变(IMM)负荷。应答肿瘤的HLA II类IMM负荷显著更高(P≤9.6e-3),高负荷与更长生存相关,尤其在NSCLC队列及低瘤内IMM异质性背景下(P<0.001)。
要点
- 黑色素瘤和NSCLC应答者的HLA II类IMM负荷均显著更高(P≤9.6e-3)。
- HLA II类IMM负荷与更长生存相关,在NSCLC及低瘤内IMM异质性时尤著(P<0.001)。
- HLA I类和II类IMM landscape largely distinct,提示II类IMM在肿瘤排斥中起互补作用。
核心结论
- HLA II类IMM负荷可识别ICB治疗后获得更长生存的NSCLC和黑色素瘤患者。
- 作者认为HLA II类IMM可能以区别于且互补于HLA I类介导应答的方式影响ICB应答。
研究设计与样本
- 分析四个队列中接受ICB治疗的黑色素瘤(n=110)和NSCLC(n=123)患者的全外显子组测序数据。
- 应用基于神经网络的MHCnuggets模型估算HLA II类IMM负荷,并计算IMM的细胞分数以评估突变克隆性。
- 评估HLA II类胚系遗传变异与II类IMM负荷对临床结局的联合影响,并从表达数据计算II类IMM负荷与肿瘤浸润淋巴细胞密度的相关性。
主要发现
- 黑色素瘤和NSCLC应答肿瘤均具有显著更高的HLA II类IMM负荷(P≤9.6e-3)。
- HLA II类IMM负荷与更长生存相关,尤其在NSCLC队列及低瘤内IMM异质性背景下(P<0.001)。
- HLA I类和II类IMM landscape largely distinct,提示II类IMM在肿瘤排斥中起互补作用。
- 较高的HLA II类IMM负荷与CD4+ T细胞浸润及程序性死亡配体1表达相关。
- 转录组分析显示高HLA II类IMM负荷肿瘤具有炎症性肿瘤微环境。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whereas human leukocyte antigen (HLA) class I mutation-associated neoantigen burden has been linked with response to immune checkpoint blockade (ICB), the role of HLA class II-restricted neoantigens in clinical responses to ICB is less studied. We used computational approaches to assess HLA class II immunogenic mutation (IMM) burden in patients with melanoma and lung cancer treated with ICB. PATIENTS AND METHODS: We analyzed whole-exome sequence data from four cohorts of ICB-treated patients with melanoma (n = 110) and non-small-cell lung cancer (NSCLC) (n = 123). MHCnuggets, a neural network-based model, was applied to estimate HLA class II IMM burdens and cellular fractions of IMMs were calculated to assess mutation clonality. We evaluated the combined impact of HLA class II germline genetic variation and class II IMM burden on clinical outcomes. Correlations between HLA class II IMM burden and density of tumor-infiltrating lymphocytes were computed from expression data. RESULTS: Responding tumors harbored a significantly higher HLA class II IMM burden for both melanoma and NSCLC (P ≤ 9.6e-3). HLA class II IMM burden was correlated with longer survival, particularly in the NSCLC cohort and in the context of low intratumoral IMM heterogeneity (P < 0.001). HLA class I and II IMM landscapes were largely distinct suggesting a complementary role for class II IMMs in tumor rejection. A higher HLA class II IMM burden was associated with CD4+ T-cell infiltration and programmed death-ligand 1 expression. Transcriptomic analyses revealed an inflamed tumor microenvironment for tumors harboring a high HLA class II IMM burden. CONCLUSIONS: HLA class II IMM burden identified patients with NSCLC and melanoma that attained longer survival after ICB treatment. Our findings suggest that HLA class II IMMs may impact responses to ICB in a manner that is distinct and complementary to HLA class I-mediated responses.
引用
- Shao XM, Huang J, Niknafs N, et al. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade. Ann Oncol. 2022. PMID: 35339648. doi:10.1016/j.annonc.2022.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。